Lauren Golden, MD
Endocrinology · New York, NYNPI 1124046503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novo Nordisk at 31.3% of the total. Reporting peaked in 2019 at $366 and has fallen 75.7% since, to $89 in 2024.
Across 20 payments — averaging $36.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$228
- Abbott$162
- Merck$113
- Cardiovascular Systems Inc.$95
- Teleflex LLC$35
- Inari Medical, Inc.$29
- plus $67 from 3 others
What the payments were for
- Food & beverage$729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $228 |
| Abbott | 8 | $162 |
| Merck | 1 | $113 |
| Cardiovascular Systems Inc. | 2 | $95 |
| Teleflex LLC | 1 | $35 |
| Inari Medical, Inc. | 2 | $29 |
| Philips North America LLC | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JANUVIA$113
How this compares
$729 in reported general payments places this provider in the 80th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 62 | $76,429 |
| JardianceEmpagliflozin | 52 | $75,137 |
| OzempicSemaglutide | 28 | $53,341 |
| RybelsusSemaglutide | 28 | $49,414 |
| JanuviaSitagliptin Phosphate | 36 | $39,758 |
| TrulicityDulaglutide | 18 | $32,374 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $21,516 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $6,241 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $3,684 |
| Novolog FlexpenInsulin Aspart | 13 | $3,084 |
| Novolog PenfillInsulin Aspart | 13 | $3,007 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $2,389 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 18 | $1,834 |
| Repaglinide | 14 | $1,040 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 16 | $1,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $228 | $102,75556 claims |
| MerckJanuvia | $113 | $39,75836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 endocrinology providers in New York.
Other endocrinology in New York
- Philip RabitoNew York$712K
- Olga LeonardiNew York$10K
- Julia Vargas-JerezNew York$590
- Sananda MoctezumaNew York$121
- Marcia KalinNew York$0
- Peter GouldenNew York$0
- Danielle BrooksNew York$0
- Nandini NairNew York$0
- Martin BarandesNew York$0
- Sharon WardlawNew York$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.